Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
Coca-Cola Funding Scientists Who Shift Focus to Exercise, Not Diet, in Weight Control
Coca-Cola is funding research by scientists who are promoting the message that maintaining a healthy weight hinges on getting more exercise and worrying less about reducing calorie intake.
The world’s largest maker of sugary drinks has partnered with scientists who are promoting this message through social media, at conferences and in medical journals, The New York Times reported.
Coke is giving financial and other support to a new nonprofit group called the Global Energy Balance Network, which claims that Americans need to exercise more and pay less attention to how much they eat and drink.
This is a misleading message and part of the beverage giant’s campaign to quell criticism about the role sugary drinks have played in rising rates of obesity and type 2 diabetes, health experts say.
They note that what people eat and drink has a much greater effect on body weight than physical activity, The Times reported.
Medicare Will Cover Costly New Cancer Drug
Medicare will pay for a new, expensive cancer medication that costs about $178,000 for a standard course of treatment, the Obama administration says.
Beginning Oct. 1, Medicare will make additional payments for patients with a particularly aggressive type of leukemia to receive Amgen’s Blincyto, The New York Times reported.
The announcement reverses a preliminary decision in April, when the government said Medicare would not pay extra for Blincyto because clinical studies were “not sufficient to demonstrate” that it offered substantial benefits to patients with acute lymphoblastic leukemia, a cancer of the blood and bone marrow.
However, the final rule to be published in the Federal Register on Aug. 17 says the administration received “additional information and input” from Amgen and other experts and now agrees with their opinion, The Times reported.
That means that Blincyto qualifies for special “add-on payments” that Medicare makes to hospitals for new treatments whose costs are not yet included in standard lump-sum payments for treating patients with a particular health problem.